Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 7/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 5/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5354771 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CTSKCTSLCTSBUSP2 | |
| SCHEMBL5142965 | 0.99 | ALDH1A1 (0.47) | ALDH1A1CTSKCTSLCTSBUSP2 | |
| SCHEMBL20568413 | 0.88 | CTSK (0.44) | ALDH1A1CTSKCTSLCTSBUSP2 | |
| SCHEMBL20568411 | 0.88 | CTSK (0.44) | ALDH1A1CTSKCTSLCTSBUSP2 | |
| SCHEMBL2054692 | 0.88 | CTSK (0.44) | ALDH1A1CTSKCTSLCTSBUSP2 | |
| SCHEMBL21994717 | 0.87 | CTSK (0.43) | CTSKCTSLCTSBCTSSPPARA | |
| SCHEMBL21994715 | 0.87 | CTSK (0.43) | CTSKCTSLCTSBCTSSPPARA | |
| SCHEMBL26119175 | 0.87 | CTSK (0.47) | CTSKCTSLCTSBCTSSPPARA | |
| SCHEMBL26119172 | 0.87 | CTSK (0.47) | CTSKCTSLCTSBCTSSPPARA | |
| SCHEMBL8271010 | 0.86 | CTSK (0.43) | ALDH1A1CTSKCTSLCTSBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4499667-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119013287-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4441069-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118613490-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-09-06 | — | — | CN | disclosed |
| EP-4373835-A1 | MACROCYLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-118076623-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4370530-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117940445-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023288213-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288213-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| EP-1899294-A1 | THERAPEUTIC AGENTS | Merck Sharp & Dohme Limited (GB) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006134341-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
| EP-0307837-A2 | Renin-inhibiting peptidyl heterocycles | ABBOTT LABORATORIES (US) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | GRIA1, GRIN1, GLRA1 | ALDH1A1 652/4885CTSK 3103/4885CTSL 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.